Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant RecipientsOtto WJ1*, Holówko WH1, Krawczyk MS1, Król MA2, Wilkowojska UM2, Wilczek E3 and Sierdzinski J4
- *Corresponding Author:
- Wlodzimierz Otto
Professor of Surgery, Dept. General
Transplant and Liver Surgery
Central Teaching Hospital
Medical University of Warsaw
Banacha 1a, Warsaw, Poland
Tel: + 48 22 599 2546, +48 602 671 176
E-mail: [email protected]
Received date: December 22, 2014; Accepted date: February 19, 2015; Published date: February 26, 2015
Citation: Otto WJ, Holówko WH, Krawczyk MS, Król MA, Wilkowojska UM, et al. (2015) Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients. Pharm Anal Acta 6:343. doi: 10.4172/2153-2435.1000343
Copyright: © 2015 Otto WJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Clinic-pathologic characteristic of hepatocellular carcinoma are mostly accounting for the tumor recurrence after liver transplantation. It is assumed that tumor angiogenesis capability contributes to the rates of post-transplant relapse, as well. The aim of study was to evaluate the contribution of the circulating hematopoietic stem cells (HSCs); endothelial progenitor cells (EPCs) and serum vascular endothelial growth factor (VEGF) to the recurrence of HCC after liver transplantation. Methods: The study was carried out on 49 cirrhotic patients with HCC within the Milan criteria. They were transplanted in 2009 and followed-up for 54 months, so far. The rates of circulating HSCs and EPCs were assessed through a phenotypic analysis of 2 ml of fresh blood in a flow cytometer. Serum VEGF concentration was measured by enzyme-linked immunoassay (ELISA). Histopathology examination of the liver explants was performed for tumor characteristic. The data were analyzed with statistical tests. Results: There were 9 deaths related to the procedure. Of 40 remaining patients the tumor recurred in 6 (15%) prior to 36 months and then in 5 (12.5%) prior to 54 months of observation. The pre-transplant rates of circulating HSCs and EPCs were significantly higher in patients with tumor relapse; Chisq=17.25, p<0.001 and Chisq=13.96, p<0.001, respectively. The differences in the serum VEGF concentration were not significant in this group, however. Conclusion: Tumor angiogenesis capability should be considered as the predictive factor of tumor relapse after liver transplantation.